Advice

in the absence of a submission from the holder of the marketing authorisation:

Dermatophagoides pteronyssinus and Dermatophagoides farina (Acarizax®) is not recommended for use within NHSScotland.

Indication under review:

  • Adult patients (18-65 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with at least one of the following conditions:
    • persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication
    • house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment
  • Adolescents (12-17 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice644KB (PDF)

Download

Medicine details

Medicine name:
Dermatophagoides pteronyssinus and Dermatophagoides farinae (Acarizax)
SMC ID:
SMC2613
Indication:

Adult patients (18-65 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with at least one of the following conditions:
• persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication
• house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment

Pharmaceutical company
ALK-Abello Ltd
BNF chapter
Immunological products and vaccines
Submission type
Non submission
Status
Not recommended
Date advice published
07 August 2023